From cancer immunotherapy to diabetes and weight loss breakthroughs, 2025’s top-selling drugs highlight how pharmaceutical ...

Eliquis (apixaban) is a brand-name oral tablet that’s prescribed for preventing or treating certain blood clots in adults. The cost of the drug with and without insurance can depend on several ...

Abstract Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

Eliquis (apixaban) is an anticoagulant used to lower the chance of stroke in people with atrial fibrillation (AFib), a common type of irregular heartbeat (arrhythmia). Most Medicare prescription ...

Approval of New Oral Anticoagulant Drugs The continued quest for an 'ideal anticoagulant' led to the US FDA's recent approval of dabigatran etexilate, a prodrug for dabigatran (Pradaxa ...

With the end of the pandemic, sales of Pfizer’s PFE COVID products, Comirnaty and Paxlovid, have declined. Though COVID revenues are declining, Pfizer’s non-COVID operational revenues improved ...

Pfizer’s PFE stock has declined 10.7% so far this year compared with a decrease of 7.7% for the industry. The stock has also underperformed the sector and the S&P 500, as seen in the chart below ...

Between now and 2028, Pfizer will lose patent exclusivity for Inlyta, Xeljanz, Prevnar 13, Eliquis, Ibrance, Mektovi, Xtandi, and Vyndaqel. Five of those eight products were blockbusters last year.

A traumatic injury, such as whiplash from a car crash, can also cause pain, or, your pain could be the accumulation of a bad ...

Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded the novel anticoagulant ...

Following Keytruda, Bristol-Myers Squibb (BMS) and Pfizer's Eliquis (apixaban), an oral anticoagulant, will be the second best-selling drug out of the top ten, with annual sales of $18.7 billion ...